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ABSTRACT
The development of personalised therapies has ushered in a new and exciting 
era of cancer treatment for a variety of solid malignancies. Yet pancreatic ductal 
adenocarcinoma (PDAC) has failed to benefit from this paradigm shift, remaining 
notoriously refractory to targeted therapies. Chemotherapy is the cornerstone of 
management but can offer only modest survival benefits of a few months with 5-year 
survival rates rarely exceeding 3%. Despite these disappointing statistics, significant 
strides have been made towards understanding the complex biology of pancreatic 
cancer, with deep genomic sequencing identifying novel genetic aberrations and key 
signalling pathways. The PI3K-PDK1-AKT pathway has received great attention due 
to its prominence in carcinogenesis. However, efforts to target several components 
of this network have resulted in only a handful of drugs demonstrating any survival 
benefit in solid tumors; despite promising pre-clinical results. p-21 activated kinase 
4 (PAK4) is a gene that is recurrently amplified or overexpressed in PDAC and both 
PAK4 and related family member PAK1, have been linked to aberrant RAS activity, 
a common feature in pancreatic cancer.  As regulators of PI3K, PAKs have been 
highlighted as a potential prognostic marker and therapeutic target. In this review, 
we discuss the biology of pancreatic cancer and the close interaction between PAKs 
and the PI3K pathway. We also suggest proposals for future research that may see 
the development of effective targeted therapies that could finally improve outcomes 
for this disease.
INTRODUCTION TO PANCREATIC 
DUCTAL ADENOCARCINOMA (PDAC)
 Pancreatic ductal adenocarcinoma (PDAC) is a 
devastating and lethal disease. Epidemiological trends 
predict that over the next two decades PDAC will overtake 
breast, colorectal and prostate cancer to become the second 
leading cause of cancer related mortality worldwide [1]. 
Due to the surreptitious nature of PDAC formation, the 
majority of patients present with advanced disease that 
is inoperable and therefore incurable. Even those few 
that undergo surgery are likely to succumb to metastatic 
spread within two years. Despite significant international 
research efforts, the last twenty years have witnessed the 
development of only two new chemotherapy regimens, 
both of which fail to improve survival by more than a few 
months for advanced disease compared with the previous 
standard of care, the nucleoside analogue gemcitabine [2, 
3]. To date, there are no effective targeted therapies for 
PDAC, highlighting the need for a better understanding 
of pancreatic tumor biology and the identification of new 
exploitable pathways.
By far the most common malignancy to arise 
from the pancreas, PDAC is a heterogeneous genetic 
disease with over 60 mutations identified per tumor [4]. 
Despite this, PDACs have several distinctive features; 
characteristic mutations in established onco- and tumor 
suppressor genes, dense surrounding stromal tissue 
and a high propensity to metastasize [5-7]. PDACs 
typically arise from one of three histological precursor 
lesions; pancreatic intra-epithelial neoplasia (PanIN), 
intra ductal papillary mucinous neoplasm (IPMN) and 
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mucinous cystic neoplasia [8]. Echoing the behavior of 
other adenocarcinomas, pancreatic cancer develops in a 
stepwise fashion from low- to high-grade dysplasia before 
culminating in malignant transformation [9, 10]. This 
process is accompanied by an increasing frequency of 
genetic aberrations [11] . The commonest mutation is at 
codon 12 in the proto-oncogene Kristen rat sarcoma  viral 
oncogene homolog (KRAS) [12]. Responsible for encoding 
a small (~21kDa) GTPase, KRAS mutations occur in nearly 
100% of PDAC tumors [12]. Often the first gene to be 
mutated in PDAC, it has also been recurrently identified in 
pre-invasive lesions and is therefore thought to be involved 
in carcinogenesis [13-16]. Constitutive activation of 
KRAS results in sustained and unregulated proliferation, 
evasion of apoptosis, re-modelling of the micro-tumor 
environment, increased cell migration and metastatic 
spread [17-20]. Murine pancreata with KRASG12D or 
KRASG12V mutations invariably develop dysplastic changes 
and subsequent invasive metastatic PDAC [16]. Three 
further genetic aberrations commonly occur in PDAC, 
namely inactivation of p16INK4A/CDKN2A (p16), Tp53 
and SMAD family member 4 (SMAD4) with a reported 
prevalence of 50-70%, 55% and 10% respectively in 
invasive PDAC [15, 21]. Whilst nearly 90% of precursor 
PanIN lesions harbor a KRAS mutation, these three ‘loss 
of function’ aberrations are less prevalent in pre-cancerous 
pathology compared with cancer samples, suggesting they 
occur later in oncogenesis. 
Extensive exome sequencing and copy number 
analyses of 142 early-stage PDAC samples have led to 
a clearer portrayal of the genomic landscape [14]. 16 
genes were found to be recurrently mutated. In addition 
to established mutations, several genes responsible for 
modifying chromatic and DNA damage repair were also 
mutated. Further aberrations in the SLIT/ROBO signaling 
pathway were identified, implicating axon guidance 
genes in pancreatic cancer development. A more recent 
genomic analysis of 456 early stage PDAC samples 
identified 32 genes that were recurrently mutated, each 
of which could be assigned to 10 pathways; KRAS, 
TGF- β, WNT, NOTCH, ROBO/SLIT signaling, G1/S 
transition, SWI-SNF, chromatin modification, DNA 
repair and RNA processing [22]. Expression analysis led 
to the classification of 4 subtypes; squamous, pancreatic 
progenitor, immunogenic and aberrantly differentiated 
endocrine and exocrine (ADEX) with clear correlation of 
histological features.
Whilst it is now clear that PDAC is a complex 
genetic disease developing from a cascade of mutations 
in pancreatic cells, this knowledge has yet to have 
a meaningful clinical impact on PDAC survival. 
Nevertheless, the identification of key pathways is vital 
in guiding the search for novel therapeutic targets as 
well as potential prognostic and predictive biomarkers. 
A pilot study of 92 patients assessed the feasibility of 
attaining PDAC tissue for genomic analysis in ‘real-time’ 
in order to perform genetic screening within a clinically 
satisfactory time-frame [23]. Three molecular targets 
were screened for: HER2 amplification, KRAS wild type 
and mutations in DNA damage repair pathway (BRCA1, 
BRCA2, PALB2 and ATM). 22 patients with these genetic 
signatures were identified. The study highlighted the 
potential for personalized therapy using high-quality 
actionable genomic data but demonstrated the challenges 
of efficiently screening bio specimens in these patients as 
well as the need for improved clinical trial options.
THE PHOSPHATIDYLINOSITIDE 3- 
KINASE (PI3K) FAMILY
Oncogenic KRAS activates a plethora of effector 
downstream pathways. The two most significant 
canonical signaling pathways are mitogen activated 
protein kinase (MAPK) (see review by Samatar et al for 
a more detailed description of the MAPK pathway) and 
the phosphatidylinositide 3-kinase (PI3K) pathway [24]. 
The PI3K-PDK1-AKT pathway is an intricate signaling 
network, regulating cell metabolism, growth, migration, 
survival and angiogenesis and therefore when aberrantly 
activated, results in oncogenesis [25]. The PI3K family 
is a group of lipid kinases that phosphorylates the 3’OH 
group of phosphatidylinositols [26]. There are three 
classes, each distinguished by structural and functional 
differences. Class 1 PI3Ks are the best characterized in 
cancer and primarily responsible for the production of D-3 
phosphoinositides in response to various growth factors, 
and it is against this class that drug development efforts to 
target this pathway have focused on [27, 28].
PI3K signaling
Each class 1A PI3K protein contains both a 
regulatory- (p85) and catalytic-(p110) subunit. p85 has 
3 isoforms p85α (p85α, p55α and p50α), p86α and p55γ 
each encoded by three genes, PIK3R1, PIK3R2 and 
PIK3R3 respectively [29]. The catalytic subunit also has 3 
isoforms (p110α, p110β and p110δ) encoded by PIK3CA, 
PIK3CB and PIK3CD respectively (Figure 1). It is the 
regulatory subunit that maintains the catalytic subunit 
in its less active state in quiescent cells and interacts 
with phosphotyrosine residues of adaptor proteins or 
activated growth factor receptors [27]. Somatic mutations 
of the aforementioned genes can lead to constitutive 
activation of the PI3K pathway and subsequent malignant 
transformation of cells [30]. In the absence of mutation, 
amplification of PIK3CA has also been identified as a 
driver in a number of epithelial tumors [31, 32]. Once 
activated, PI3K converts the lipid phospatidylinsotide-
4,5-bisphophate (PIP2) to phosphatidylinositide 3,4,5- 
triphosphate PIP3 (Figure 2). Proteins with pleckstring 
homology (PH) domains travel to the sites of PI3K 
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activation and bind to PIP3. Two specific serine/threonine 
kinases PDK1 and AKT are subsequently both brought 
into close proximity of each other by PIP3[27]. PDK1 
activates AKT by phosphorylation of the threonine site 
(T308) in AKT. The serine site (S473) can be activated by 
several kinases including mTOR complex 2 (mTORC2), 
PDK-1, integrin-linked kinase (ILK) and AKT itself [33-
35].
This critical signal between PDK1 and AKT 
promotes cell growth and survival by various mechanisms 
including the inhibition of the pro-apoptotic factors 
BAD and BAX [36]. One of the major downstream 
effectors of AKT is mTOR complex 1 (mTORC1) 
which is responsible for growth factor signaling, AMP 
levels, oxygen availability and nutrition [37]. The tumor 
suppressor gene phosphatase and tensin homolog deleted 
on chromosome 10 (PTEN) dephosphorylates PIP3, 
converting it back to PIP2, subsequently terminating this 
process and is therefore a critical negative regulator of 
the PI3K pathway. Arguably the most important tumor 
suppressor gene second only to p53 in many malignancies, 
loss of PTEN activity can result from mutation, promoter 
methylation, phosphorylation or delocalization from the 
plasma membrane [38].
Although there is clear evidence implicating 
Class1A PI3Ks in PDAC oncogenesis, Class 1B has also 
Figure 1: Different classes of the PI3K family. The phosphatidylinositol 3-kinase (PI3K) family comprises of three classes with several 
isoforms which catalyses different substrates. Class I PI3K consists of Class IA and Class IB Pi3Ks, both converting phosphatidylinositide 
4,5- bisphosphate (PIP2) into phosphatidylinositide 3,4,5- triphosphate (PIP3). Class IA PI3Ks are activated by receptor tyrosine kinases 
(RTK) which can activate catalytic isoforms p110α, β and δ through the adaptor subunit p85. There are five known adaptor subunit isoforms, 
namely p85α, p85β, p55α, p55γ and p50α. Class IB PI3K are activated by G-protein coupled receptors (GPCRs) and has one catalytic 
subunit p110γ and two known regulatory subunits p101 and p87. Phosphatase and tensin homolog (PTEN) phosphatase inactivates Class I 
PI3K signaling. Class II and class III PI3Ks are known to catalyze phosphatidylinositol (PI) into phosphatidylinositol 3-phosphate (PI3P). 
Myotubularin (MTM) phosphatase inactivates both class II and class III PI3K signaling. Class II PI3Ks consists of a catalytic subunit with 
three isoforms PI3K-C2 α, β, and γ, but does not associate with any regulatory subunits. Class III PI3K is composed of a VPS32 catalytic 
subunit and a VPS15 regulatory subunit, often bound in a multiprotein complex.
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been implicated in tumor formation. Indeed, P110ϒ is 
expressed in patients with pancreatitis suggesting it has 
a role in inflammation, which in turn is thought to be a 
precursor for malignancy. Pre-clinical kinetic assays 
have determined that p110β and ϒ are required for AKT 
activation [39].
PI3K pathway in PDAC
The PI3K pathway appears to be critical in the 
development and maintenance of PDAC. In a recent 
study of transgenic mice with KRASG12D mutations, PDK1 
inactivation prevented PanIN and PDAC formation [40]. 
The mice had a normal survival with pancreata of normal 
morphology but signs of cellular stress as expected in 
the presence of mutated KRAS. This finding suggests 
that PDK1 activity, a pivotal component of the PI3K 
pathway, is a critical driver of pancreatic dysplasia. This 
is contrary to a previous report in non-small cell lung 
cancer, where the RAF proto-oncogene serine/threonine 
protein kinase was reported to be essential for KRAS 
driven adenocarcinoma of the lung rather than PDK1, the 
absence of which did not reduce tumor formation [41, 42]. 
Yet when CRAF was ablated in KRASG12 mutated mice, 
it appeared to have no inhibition on PDAC formation. 
This suggests that although mutated KRAS is a critical 
oncogene in several malignancies, its effectors vary 
depending on tissue type, demanding careful evaluation 
of each downstream pathway in differing cancers [40].
Although whole genome and exome sequencing 
have confirmed that PTEN mutations are uncommon 
in PDAC samples, PTEN inactivation appears to have 
a significant role. In 54 human PDAC samples, 70% 
displayed no or low PTEN expression and 68.5% of 
tumors exhibited at least moderate phosphorylated pan-
AKT-Ser473 expression compared to surrounding stroma 
[43]. There was also a significant negative correlation 
between PTEN expression and pan-AKT phosphorylation 
suggesting that activation of the PI3K pathway via PTEN 
Figure 2: The class I PI3K signaling pathway through receptor tyrosine kinases. Upon binding of growth factors to receptor 
tyrosine kinases (RTKs), the receptor gets activated through the phosphorylation of YXXM motifs. The activation of the RTKs will result 
into the recruitment of p85 and the p110 subunits, which together forms the phosphatidylinositol 3-kinase (PI3K), to the plasma membrane 
in order to phosphorylate the phosphatidylinositide 4,5- bisphosphate (PIP2) and transforms it into the phosphatidylinositide 3,4,5- 
triphosphate (PIP3). Alternatively, the PI3Ks can also be activated by KRAS, which alone can activate downstream signaling pathways 
such as the RAF-MEK-ERK pathway and result into cell proliferation and survival. The PI3K signaling pathway is normally inactivated 
through Phosphatase and tensin homolog (PTEN) converting PIP 3 back into PIP2. PIP 3 acts as a second messenger that can recruit AKT to 
the plasma membrane and activate downstream effectors such as Rac1, CDC42 and phosphoinositide-dependent kinase PDK1. Activated 
PDK1 is able to phosphorylate recruited AKT on the Thr308 residue. In addition, MTOR complex 2 (MTORC2) is able to phosphorylate 
AKT on the Ser473 residue. Phosphorylation of either or both residues of AKT results in downstream signaling events such as cell growth, 
protein synthesis and angiogenesis through MTORC1. Furthermore, activated AKT can also promote cell survival through inhibiting 
cellular processes such as glucose metabolism and apoptosis through blocking glycogen synthase kinase 3β (GSK3β) and pro-apoptotic 
members of the bcl-2 family; BAD and BAX respectively. Moreover, AKT can also inhibit apoptosis through the activation of Nuclear 
factor κβ (NF-κβ), and promote migration.
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loss or AKT activation is an important driver in PDAC. 
Furthermore, high-resolution array Comparative genomic 
hybridization (CGH) analysis of 61 primary xenografts 
or epithelial enriched primary tumor cells revealed a 
deletion of either one or two copies of the PTEN locus 
in 9/61 samples and gain/amplification of the AKT2 
isoform in 12/61 samples. One samples harbored both 
genetic events. Transgenic mice with heterozygoys loss 
of PTEN developed highly invasive pancreatic cancers 
compared with PTEN wild type mice. All 11 mice with 
total loss of PTEN, developed rapidly progressive acinar-
ductal metaplasia [ADM] and PanIN formation but there 
were only occasional invasive cancers. However, the lack 
of invasion is complicated by the early death of these 
mice which did not survive beyond 3 weeks; probably 
due to pancreatic insufficiency. Further analysis of the 
littermates of KRAS mutated and PTEN heterozygous mice 
at 4,6,8 and 10 weeks revealed that the pancreas of PTEN 
heterozugous mice exhibited an increased frequency and 
size of ADM and PanIN lesions, a more profound stromal 
reaction and moderately elevated phosphorylated AKT. 
These findings suggest that in KRAS mutated PDAC; 
PTEN can repress PI3K signaling and restrain cancer 
progression. A further study looking at the role of the PI3K/
AKT pathway in PDAC formation, examined mice with a 
latent oncogenic PIK3CA mutation (encoding p110αH1047R) 
allele silenced by a lox-stop-lox (LSL) cassette as a knock-
in [40]. Transgenic expression of this mutation resulted 
in increased PIP3 levels in murine pancreata, similar to 
the expression seen in KRAS mutated mice. Histological 
review of the PIK3CA mutated mice revealed a greater 
presence of ADM and all mice subsequently developed 
PanIN at a rate similar to KRASG12D mice. Analysis of 
tissue samples revealed similar expression of several 
downstream components of the PI3K pathway including 
phosphorylated AKT-Ser473 and AKT-Thr308, pan-AKT 
and phosphorylated GSK3β-S in both models. Aged 
mice with either a PIK3CA or KRAS mutation developed 
PDAC within 800 days with comparable survival times 
and patterns of metastatic spread. Importantly in the 
tissue taken from the PIK3CA mutated mice, there was no 
evidence of RAS activation, excluding the possibility of 
upstream RAS being responsible for driving progression. 
PDK1 was then inactivated in murine pancreata using 
floxed PDK1 mice to test the importance of PDK1 in 
PDAC formation. Total PDK1 inactivation appeared to 
block PanIN and PDAC development in the KRASG12D 
mouse models, resulting in normal life expectancy and 
PI3K/AKT inactivation. Deletion of one PDK1 allele 
did not alter the prevalence of PanIN and PDAC. Loss 
Figure 3: Domain structure of PAK family proteins. There are 6 PAK family kinases which are divided into 2 groups. Group I 
and II PAKS share a common domain consisting of an N-terminal p21-GTPase binding domain (GBD) and a Cterminal serine/threonine 
kinase domain. Group I PAKS have an Auto inhibitory Domain (AID) overlapping the GBD (GTPase Binding Domain), while the Group 
II PAKS contain a putative AID sequence. Group I PAKS also contain a PIX binding site in the central region. PAK4 contains a Rho-GEF 
interacting domain.
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of PDK1 also reduced the phosphorylation of AKT at the 
threonine site and its downstream effector GSK3β-S9.
Given this wealth of evidence supporting a role for 
the PI3K pathway in disease progression it is perhaps not 
surprising that PI3K inhibitors have been tested in some 
of the PDAC model systems. A selective oral pan-class 
I PI3K inhibitor, GDC0941 has been used to treat mice 
harboring a KRASG12D mutation [40]. After 14 days of 
treatment, GDC0941 reduced both PDAC tumor growth 
and phosphorylation of AKT-Thr308. This led to disease 
stability in contrast with vehicle-treated mice where rapid 
disease progression was observed. Post-mortem tissue 
analysis also revealed decreased proliferation markers 
in the GDC0941 treated tumors. In addition to the KRAS 
mutated mice, primary patient-derived PDAC cells were 
transplanted orthoptically in to the pancreas of immuno-
deficient mice. These mice were subsequently treated with 
GDC0941 and similar tumor suppressive events were 
recorded. These studies confirm that the PI3K-PDK1-AKT 
pathway is an important driver for PDAC.
A key hallmark of PDAC is the dense stroma 
surrounding the tumor. Cancer cells are encased in a 
mesh composed of stromal fibroblasts, endothelial cells 
and immune cells; the roles of which have yet to be fully 
established [44]. Significant debate surrounds the effect 
of the stroma on cancer progression. Previously thought 
to be protective of the tumor and a barrier to adequate 
drug delivery, recent studies have shown that depleted 
stroma in transgenic mice led to poorer survival with 
more aggressive cancers suggesting the stroma may in fact 
hinder tumor progression [45]. A recent study investigating 
heterocellular signaling (between the cancer cells and 
stromal cells) has revealed that KRASG12D PDAC cells 
secrete growth factors including MFCSF, GCSF cytokines 
and the growth morphogen sonic hedgehog (SHH) 
which act on the stromal cell compartment, particularly 
pancreatic stellate cells (PSC) [46]. Interestingly this 
study reported that KRASG12D expression induces canonical 
ERK1/2 activation, but found no evidence that AKT was 
activated in a cell-autonomous way. However, whilst 
Figure 4: The potential role of PAK in PI3K signalling. PAK could be a key mediator in the PI3K-AKT signalling axis through 
direct activation by PI3K A. and through the activation via PIP3-RAC1 B. Furthermore, direct activation of PAK through KRAS has been 
suggested C. Activation of PAK has been shown to activate AKT in kinase dependent manners through the phosphorylation of either S473 
D. or T308 E. or both residues, and through a kinase independent manner F. The possibility of a negative or positive feedback loop by AKT 
on PAK G. has not been investigated thus far. Other factors that could activate PAK are yet to be identified H.
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AKT activation did not appear to be via expression of 
KRASG12D, tumor cell AKT substrates, such as GSK3β, 
were elevated in the PDAC cells suggesting that KRASG12D 
activates AKT reciprocally via stimulation of PSC rather 
than cell-autonomously. This emphasizes the need for 
future genomic and proteomic studies encompassing 
heterocellular rather than homocellular signaling in 
PDAC; where the stroma is present proposing AKT as 
a potential focal point where reciprocal signaling could 
occur.
P-21 ACTIVATED KINASES
Targeting either RAS or PI3K pathways has potential 
limitations, as there is clear evidence of complex cross-
talk between the two [47]. Promising treatment strategies 
using MEK inhibitors for example, unwittingly activated 
the PI3K pathway by a negative feedback loop [48]. 
Whilst novel drugs targeting PI3K and its downstream 
targets remain in development, several have failed to show 
benefit in clinical trials. Unless clear oncogenic addiction 
to therapeutic targets has been demonstrated, the lack of 
patient stratification using clear predictive biomarkers in 
these trials may explain these recent failures. It is therefore 
prudent to consider alternative strategies such as targeting 
components that can directly and indirectly interact with 
the PI3K pathway including the PAKs.
There is emerging evidence to suggest that aberrant 
activation of PAKs can lead to tumorigenesis [16, 49]. 
Indeed, PAK overexpression has been identified in 
various solid tumors including breast, colon, prostate 
and importantly in PDAC [49]. There also appears to be 
links between PAK activity and the PI3K pathway. The 
PAK family comprises six non-receptor serine/threonine 
kinase members, divided into group 1 (PAK1-3) and group 
2 (PAK4-6) (Figure 3). Each sub-group has shared and 
distinguishing features including differences in regulation. 
Even amongst the subgroups, several distinctions occur. 
Transgenic knock out (KO) models of PAK5 or PAK6 
results in viable healthy litter, whereas PAK4 KO is 
embryonically lethal [50, 51]. (See reviews by King et 
al and Radu et al for more information [49, 52]). PAKs 
are effectors of Rho GTPases Cdc42 and Rac, and 
upon activation by upstream signaling, mediate several 
physiological processes[53]. These include cell survival, 
growth and cytoskeletal dynamics affecting cell adhesion, 
motility and morphology [54]
PAK signaling
Phosphorylation of PAK members by PI3K, AKT 
and PDK1 can modulate various downstream signal events 
including several cellular process that, when dysregulated 
could contribute to the hallmarks of cancer [55-57]. 
Activation of members of the PAK family has been shown 
to promote cell survival and anti-apoptotic signaling. It has 
been reported that PAKs promote anchorage independent 
growth on soft agar in vitro, suggesting its contributions to 
oncogenic transformation [58-62]. Furthermore, aberrant 
PAK expression via direct phosphorylation of downstream 
BAD, or indirectly through Raf-1, leads to reduced binding 
of the death protein BAD to BCL-2 and thus prevents 
the release of pro-apoptotic factors [63-66]. In addition, 
there is evidence to suggest PAK2 and PAK4 could inhibit 
apoptosis independently from BAD phosphorylation 
through phosphorylation of caspase 7 and inhibition of 
caspase 8 respectively [67, 68]. PAK1 activates the nuclear 
factor kappa-light-chain-enhancer (NF-κβ) pathway 
resulting in resistance to apoptosis and promoting cell 
growth and angiogenesis [69]. Overexpression of PAK5 
inhibits caspase-8 activity and subsequent inhibition of 
camptothecin induced apoptosis [70].
In addition to survival and anti-apoptotic signaling, 
PAK is also associated with cell cycle progression and 
cell proliferation [62, 71-73]. This was demonstrated to 
be via AKT, ERK and Wnt mediated signaling in colon 
cancer [74, 75]. PAK1 can also activate the ERK pathway 
via Mitogen-activated Protein Kinase Kinase (MEK) 
phosphorylation in a kinase independent manner, with 
subsequent increased Cyclin D1 expression, leading to 
cell cycle progression [76]. PAK4 regulates cell cycle 
progression through phosphorylation of SMAD2/3 of the 
TGF-β pathway, and by mediating the expression of cell 
cycle regulators p21, Cyclin D1 and CDC25A [77, 78].
As downstream effectors of the Rho GTPases 
Cdc42 and Rac, PAKs also play a crucial role in cancer 
cell migration and invasion, which could contribute 
toward metastases formation. PAKs are involved in 
cytoskeletal remodeling through increased cellular 
contractility via phosphorylation of myosin light chain 
(MLC), and interaction with microtubules through 
phosphorylation of GEF-H1[79, 80]. Furthermore, PAKs 
can induce actin filament elongation and reduce actin 
disassembly by phosphorylation of LIM kinase (LIMK), 
and actin polymerization through phosphorylation of 
p41-Arc, inducing Arp2/3 complex formation [80-82]. In 
addition, PAKs can modulate lamellipodia and filopodia 
formation, rapid turnover of focal adhesions by paxillin, 
and membrane ruffling through filamin A to promote 
increased cell motility [83-86]. Moreover, cell-cell 
junctions were found to be inhibited by PAK1 induced 
Snail activation, promoting dissemination of cancer cells 
by inducing epithelial mesenchymal transition (EMT) 
[87, 88]. PAK6, one of the least well characterized family 
members, is required for hepatocyte growth factor (HGF) 
activated carcinoma cell-cell disassociation. PAK6 can 
drive cell-cell disassociation via an IQGAP1/E-cadherin 
complex leading to the phosphorylation of β-catenin 
and the subsequent disruption of cell-cell adhesions 
and β-catenin and PAK6 both localize to cell junctions 
[89]. PAK6 localization to the cell-cell adhesions occurs 
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via the N-terminus and is Cdc42 dependent [90]. In 
osteosarcoma and breast cancer cell lines, PAK4 inhibition 
led to defects in the cell polarization and suppressed 
β-catenin phosphorylation [91]. Further work needs to 
be performed to translate these concepts to PDAC cells 
but they highlight the potential that PAKs have in cell-cell 
disruption and subsequent dissemination.
It has also been reported that the promotion of 
invasion through extracellular matrix degradation 
can be mediated by PAK-induced secretion of matrix 
metalloproteinases MMP-1, MMP-2, MMP-3 and MMP-9 
[77, 92, 93]. Conversely, PAK inhibition leads to reduced 
migratory and less invasive potential of cancer cells [93-
99].
Several reports have suggested that PAKs are 
also involved in other cellular processes such as 
vasculogenesis, angiogenesis and metabolic activity [100-
103]. However, it is important to note that PAKs have also 
demonstrated numerous non-kinase dependent functions 
[66, 68, 76].
PAKs and cancer
Overexpression of PAKs 1,2,4 and 6 appear to 
correlate with a more aggressive phenotype of cancer 
suggesting its potential as a prognostic biomarker 
[104-109]. In a study using 153 paraffin embedded 
tissue samples retrospectively collected from patients 
with advanced ovarian cancer, there was a significant 
association between increased PAK4 expression and 
reduced overall and disease free survival, reduced chemo-
sensitivity and an increased presence of metastases [77]. 
PAK1 on chromosome 11q13 and PAK4 on chromosome 
19q13.2 are the most commonly overexpressed members 
of the PAK family in malignancy. Amplified 11q13 and 
subsequent PAK1 expression has been identified in ovarian 
cancer and in breast cancer where 11q13 amplification 
is associated with poor prognosis. Increased PAK1 
expression is also present in BRAF wild type melanoma 
compared with BRAF mutated disease. Chromosome 
19q13.2 is recurrently amplified in PDAC, oral squamous 
cell carcinoma, breast cancer and ovarian cancer [52].
Even in the absence of genetic amplification, 
down-regulation of micro RNA 7 (miR-7) has led to 
overexpression of PAK1 in vitro [108, 110-114]. Similarly, 
PAK2 and PAK4 expression in cancer cells in vitro were 
reported to be negatively mediated by miR-224 and miR-
145 or miR-199a/b3p respectively, suggesting a regulatory 
role for microRNAs on PAK expression [115-117].
PAK and PDAC
Whilst the exact role of PAKs in the development 
of PDAC has yet to be established, higher levels of PAK1 
and PAK4 have been reported in PDAC. A study looking 
at 202 human PDAC tissue samples found that PAK1 
was overexpressed in 82% of them [118]. Furthermore, a 
recent study of 72 paraffin-embedded primary pancreatic 
cancer samples and 20 liver metastases from PDAC 
patients, reported that PAK1 expression was elevated 
in primary pancreatic cancer tissue compared with that 
taken from metastases [117]. PAK1 expression appeared 
to correlate with improved overall survival (high PAK1 
expression was associated with an increased median 
overall survival of 23.3 months compared with 12.0 
months; p=0.004; hazard ratio for death = 0.4). However, 
there was no correlation with PAK1 expression and tumor 
stage or clinical characteristics. There are limitations 
to interpreting this data as it is a retrospective analysis 
and further prospective work is needed to validate these 
findings. Interestingly, these studies do not reflect in 
vitro reports where high levels of PAK1 expression are 
consistently associated with a more aggressive phenotype. 
Indeed, over expression of PAK1 in the PDAC cell line 
MiaPaCa2 resulted in increased proliferation, larger 
number of colony formation and increased migration 
[119]. Whilst in KRAS wild-type pancreatic cancer 
cell lines PAK1 overexpression led to increased colony 
formation. Furthermore, PAK1 depletion led to reduced 
migration and invasion suggesting PAK1 may play a more 
prominent role in KRAS-independent PDAC. In addition, 
a further study also confirmed that PAK1 depletion led to 
reduced proliferation in the PDAC cell lines MiaPaCa2 
and Panc1 [120]. Thus, whilst it is clear that PAK1 over 
expression is present in PDAC tissue compared with 
normal tissue, its precise in vivo role in carcinogenesis and 
metastatic spread needs to be investigated further.
PAK4, a member of the group 2 PAKs, is also 
overexpressed in PDAC. CGH analysis on cDNA 
microarray of 13 PDAC cell lines identified 24 
independent amplicons. Copy number increases were 
frequently seen at three regions of chromosome 19 
(19p13.3, 19q13.1 and 19q13.3). Analysis of these loci 
revealed that PAK4 at 19q13.1 was frequently expressed 
at higher levels, correlating with increased copy number 
changes [113]. A subsequent study using representational 
oligonucleotide microarray studies analyzed 92 PDAC 
samples [121]. 22 PDAC cell lines, 26 surgically resected 
early stage PDAC samples and a further 24 xenografts of 
surgically resected PDAC samples were used to assess 
copy number variations. To increase sample size, data 
from the analysis of 16 primary PDAC tissue samples and 
4 cell lines that had previously been published were added 
to the new samples resulting in a total of 92 individual 
PDAC samples. Several previously established genetic 
amplifications and deletions were identified including 
Tp16/CDKN2A (Ink/Arf), TP53, c-MYC, KRAS2, 
MADH4, TERT, EGFR, ERBB2 and znf217 as well as 
focal amplification at 19q13 in 5 patient samples and 2 
cell lines. Candidate oncogenes from this region were 
then mapped and using immunohistochemical labeling, 
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PAK4 was identified as being at the ‘epicenter’ of this 
region. In all samples harboring genomic amplification 
at 19q13, PAK4 protein expression was higher than 
normal. To determine the relationship between PAK4 
and mutated KRAS, the KRAS2 gene was sequenced in 
the tumor samples with PAK4 amplification. Codon 12 
was mutated in 4 of the 5 samples and 3 of these samples 
also had genomic amplification and overexpression of 
KRAS2. These results led the authors to suggest that the 
PAK4 and RAS pathways may be positively associated. 
However, one sample had no mutation in KRAS2 or PAK4, 
thus PAK4 amplification may also occur in the absence of 
KRAS activation.
qRT-PCR has also revealed increased PAK4 
expression in multiple PDAC cell lines with or without the 
amplification suggesting PAK4 expression is not always 
dependent on genetic overexpression [122]. Further 
investigation revealed that reduced PAK4 expression in 
pancreatic cancer cells leads to a significant reduction 
in anchorage independent growth. Moreover, expression 
of a constitutively activated PAK4 protein promoted 
increased migratory capacity which could be attenuated by 
reduced PAK4 expression [123]. Although current studies 
demonstrate an oncogenic role of PAKs in PDAC, more 
research is needed to identify their exact mechanism and 
contribution towards PDAC progression. Nevertheless, 
these findings suggest the PAKs have a central role in 
the maintenance of PDAC, highlighting their potential as 
therapeutic targets.
PAK and the PI3K pathway
There is evidence that the PAK family can interact 
with various components of the PI3K pathway (Figure 4). 
Indeed, qPCR analysis in oral squamous cell carcinomas 
(OSCC), revealed co-existing PIK3CA and PAK1 
amplification in 37% of recurrent tumor samples[124] . 
PI3K is known to stimulate the small G protein Rac, which 
in turn is a direct activator of both PAK1 and AKT[56]. In 
colorectal cancer (CRC) cells, reduced PAK 1 expression 
led to reduced AKT phosphorylation which correlated 
with a subsequent decrease in cell proliferation, migration, 
invasion and survival[75]. A link between PAK and AKT 
has also been reported in monkey fibroblast like (COS-1) 
cells where expression of a dominant negative mutant of 
PAK1, inhibited AKT1 phosphorylation [125]. In addition, 
the PAK1 kinase domain serves as a scaffold allowing 
AKT stimulation by PDK1, and aids recruitment of AKT 
to the cell membrane. Subsequent silencing of PAK1/
PAK2 expression also reduced activation of endogenous 
AKT confirming that PAK1 and PAK2 are required for 
phosphorylation of AKT. Surprisingly over expression 
of PAK1 kinase negative mutants also effectively led to 
the phosphorylation of AKT, suggesting that PAK1 can 
drive activation of AKT in a kinase independent manner. 
These studies also demonstrated that AKT1 could be 
co-immunoprecipitated with PAK1. Indeed, AKT co-
immunoprecipitation with PAK1 is also reported in platelet 
cells further confirming the close interaction between PAK 
and AKT [126]. In breast cancer cells, endogenous levels 
of Rac1, PI3K and PAK1 were all stimulated following 
treatment with epidermal growth factor (EGF) leading 
to increased migration[127], however in cells expressing 
a PAK1 kinase dead mutant this migratory response to 
EGF was significantly diminished. Interestingly, the 
non-specific PI3K pathway inhibitor LY294002 reduced 
phosphorylation of PAK1 in these cells placing PAK1 
downstream of PI3K suggesting there may in fact be 
a feedback loop by which the two interact. Recently 
increased PAK1 expression was associated with activated 
AKT with a trend towards significance (p=0.05) in 
human squamous cell skin cancer (SCC) samples [128]. 
Transgenic mice harboring KRASG12D mutations were 
bred with PAK1 knock out mice to produce mice that 
were wild type, heterozygous or knockout for PAK1. The 
control mice, K5-rTA::tet-KRASG12D, developed irregular 
lesions on the skin as early as five days which invariably 
transformed to SCC malignancies. The Pak1+/- mice took 
10 days to develop skin lesions compared to control mice 
and the Pak-/-  mice took 25 days. The PAK-/- mice also had 
significantly longer survival. In the KRASG12D mice, the 
presence of PAK1-/- led to a decrease in phosphorylated 
AKT and downstream targets, mTOR, p70, S6K and 
S6. Interestingly, two PAK inhibitors, (PF03758309 that 
suppresses groups 1 and 2 PAK and FRAX-597 that 
suppresses group 1 PAK) led to marked tumor regression 
in the K5-rTA::tet-KRASG12D mice. Western-blot analysis 
of tumor samples revealed a reduction in threonine 
phosphorylated AKT. However, treatment with the AKT 
inhibitor GSK690693 did not deliver tumor regression 
thus the importance of AKT signaling in this context 
remains to be elucidated. There is also evidence that PAK 
can be mediated by PI3K independent from RAS activity. 
In breast cancer cells with both Her2 amplification and 
PIK3CA mutations, treatment with a pan-PI3K inhibitor 
GDC0941 led to reduced AKT and Rac1/ERK activity 
[47]. RAS activity was paradoxically not suppressed 
but induced, suggesting that loss of ERK signaling can 
occur via a RAS independent pathway. Whilst loss of 
KRAS via SiRNA knockdown failed to suppress ERK 
phosphorylation in T47D cells (supporting the theory that 
this event can occur independently of KRAS activity) in a 
pancreatic cancer cell line, KRAS knockdown suppressed 
phospho-ERK activity suggesting that there may be 
heterogeneity in these pathways depending on tumor type.
In contrast there have been specific studies of 
PAK4 pathways in PDAC with evidence that PAK4 
can modulate the activity of AKT. In pancreatic cancer 
cell lines stable PAK4 depletion led to a significant 
decrease in phosphorylated AKT levels [124]. Moreover, 
PAK4 depleted cells exhibited reduced proliferation 
and increased levels of cell death with a concomitant 
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decrease in the accumulation of NF-kβ within the 
nucleus. In MDA-MB-231 breast cancer cells, elevated 
levels of PAK4 expression correlated with an elevated 
level of phosphorylated AKT and a more invasive 
phenotype [129]. Consequently, PAK4 depletion by 
SiRNA knockdown resulted in reduced phosphorylated 
AKT and reduced activity of mammalian target of 
rapamycin (mTOR), a downstream effector of AKT. In 
contrast a kinase active PAK4 (S474E) enhanced PI3K/
AKT signaling. Interestingly a kinase inactive mutant of 
PAK4 (K350A/K351A) continued to up drive increased 
levels of phosphorylated AKT suggesting the activity of 
PAK4 may be both kinase dependent and independent. A 
study of cisplatin resistant (CDDP) gastric cancer cells 
also confirmed that in PAK4 SiRNA depleted cells there 
is a reduction in phosphorylated AKT, whilst total AKT 
levels were unchanged [130]. PAK4 silenced CDDP 
gastric cancer cells were then subcutaneously injected 
into nude mice. Analysis of subsequent tumors with 
immunohistochemical staining revealed there was reduced 
expression of phosphorylated AKT in PAK4 depleted 
compared with wild type tumors. Conversely, treatment 
with the PI3K inhibitor LY294002 in the wild type CDDP 
gastric cancer cells, led to a reduction of phosphorylated 
PAK4 compared with control cells without affecting total 
PAK4 expression. This was not reproduced with a MEK/
ERK inhibitor. These results suggest that PAK4 and the 
PI3K/AKT pathway can reciprocally activate each other.
TARGETING THE PI3K AND PAK 
PATHWAY IN PDAC
Despite a paradigm shift toward molecularly 
targeted therapies in many solid malignancies, 
management of advanced PDAC has largely been left 
unaffected by these changes and response to cytotoxic 
chemotherapy is poor. Two chemotherapy regimens have 
improved survival of advanced PDAC in recent years. 
FOLFIRINOX, a triplet combination which offers a 
median overall survival (OS) of 11.1 months compared 
with 6.8 months for gemcitabine alone in a phase III 
trial (p<0.001) [3]. An alternative treatment regimen 
is Nab-Paclitaxel and gemcitabine which improved 
median OS to 8.5 months compared with 6.7 months for 
gemcitabine (p<0.001) [2]. The only phase III trial of a 
targeted therapy to meet its primary endpoint of improved 
survival was the anti-epidermal growth factor (EGFR) 
small molecule inhibitor erlotinib, which when combined 
with gemcitabine offered a marginal survival benefit of a 
couple of weeks [131]. Unlike lung cancer, the presence 
of an EGFR mutation was not predictive of response. Yet 
analysis of patients who experienced cutaneous toxicity 
revealed that the presence of a skin rash was associated 
with a higher likelihood of achieving disease control (P 
= .05) after other prognostic factors were controlled for. 
These results seemed to suggest that there may be a cohort 
of patients who responded to therapy, highlighting the 
need for predictive biomarkers. The failure of molecularly 
targeted therapies so far suggests that patients need to be 
stratified by genomic expression and treated according 
to suspected oncogenic drivers. Therefore, the search for 
more effective therapy has fueled the evaluation of several 
novel targets for PDAC.
The RAS/PI3K/PDK1/AKT pathway is an exciting 
target. Targeting RAS has proven challenging with 
previous attempts to inhibit KRAS unsuccessful due to 
the inability to find an allosteric binding point on mutated 
RAS. This is likely due to its high binding affinity with 
GTP. Post-translational modification of RAS proteins 
(required for membrane anchorage) using farnesyl-
transferase inhibitors failed to improve survival in clinical 
trials when used in conjunction with chemotherapy [132]. 
Further attempts using an orthosteric inhibitor of the RAS-
SOS interaction are promising but have yet to make it to 
clinical trials [133]. Small molecules that can irreversibly 
bind to a common mutant KRAS (G12C) are in development. 
The discovery of a new allosteric regulatory site meant 
these novel inhibitors bind to a newly discovered 
regulatory site leading to disruption of both switch-1 and 
switch-2 leading to reduced GTP binding and subsequent 
activity [134]. Further studies are warranted to determine 
clinical activity of these agents. Targeting a protein 
upstream in prominent oncogenic pathways can be a 
double-edged sword with normal cellular function at risk 
of unwarranted inhibition, resulting in potential toxicities. 
Therefore, research has focused on down-stream targets. 
Careful selection of the right constituent of the pathway 
is paramount to maximize efficacy without compromising 
safety.
Targeting PI3K pathway
Blockage of the PI3K pathway has yielded some 
promising results. Several agents that target various 
components of the PI3K pathway are in development 
(Table 1). These include pan-Class1 and isoform-specific 
PI3K inhibitors, dual PI3K -mTOR inhibitors, pan and 
isoform-specific AKT inhibitors and allosteric mTOR, 
AKT and PDK1 inhibitors [135]. The PDK1 inhibitor 
BX912, the dual class 1 PI3K-mTOR inhibitor NPV-
BEZ235 and the AKT inhibitor MK-2206 all show 
evidence of blocking acinar-ductal metaplasia [136] 
formation in primary PDAC xenografts. NVP-BEZ235, 
demonstrated inhibited tumor growth in orthoptic 
pancreatic xenografts [137]. The potent and selective 
oral pan-class 1 PI3K inhibitor GDC0941 effectively 
inhibited the growth of primary KRASG12D murine and 
primary human patient derived PDAC cells in vivo. In 
KRAS mutated mice, GDC0941 efficiently blocked tumor 
growth with decreased cell proliferation after 14 days of 
treatment [40]. Treated cells showed a reduction in the 
phosphorylation of AKT-Thr308 highlighting AKT activity 
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as a potential surrogate marker for disease response. 
GDC0941 has been evaluated in an early phase study, 
with confirmation of pharmacodynamics response and 
preliminary evidence of efficacy [138]. Ongoing trials 
are underway with GDC0941 and other pan-Class I PI3K 
inhibitors, but are unlikely to yield meaningful responses 
as single agents due to complexity of feedback loops and 
crosstalk across linked signaling pathways.
Dual inhibition to counteract this cross-pathway 
activation is therefore likely to yield more effective 
results. The MEK1/2 inhibitor, AZD6244 was tested in 
combination with two PI3K inhibitors NVP-BKM120 
or GDC0941 in transgenic mice and PDAC cell lines. 
Although MEK inhibition alone was cytostatic, the 
combination with either PI3K inhibitor led to apoptosis. In 
KRASG12D mice, dual inhibition delayed PDAC formation 
and improved survival although responses were not 
durable [139]. The combined use of the MEK inhibitor 
GSK1120212 and the AKT inhibitor GSK690693 resulted 
in statistically significant synergy in PDAC cell lines with 
decreased phosphorylation of the downstream effector of 
AKT, RPS6, compared with either agent alone suggesting 
AKT inhibition could potentiate the response of targeting 
MAPK [140].
Targeting PAK
PAK inhibitors have also demonstrated modest 
efficacy in cell lines although preliminary uses of group 1 
PAK inhibitors were largely unsuccessful. Group 1 PAKs 
have a large ATP binding pocket with high conformational 
flexibility that likely impeded the identification of high-
affinity ligands [141, 142]. However, the PAK1 inhibitor 
FRAX597 has shown evidence of decreasing PDAC cell 
proliferation, migration and survival. In addition when 
combined with the chemotherapeutic agent gemcitabine, 
FRAX597 synergistically inhibited PDAC proliferation 
both in vivo and in vitro [120].
PAK4 is also a promising target. PF-3758309 is a 
potent (Kd=2.7nM), ATP competitive, pyrolopyrazole 
inhibitor of PAK4 [143]. As selective downstream 
targets of PAK4 are unknown, a PAK4 specific assay 
was constructed with an inducible expression of a PAK4 
Table 1: Table of drug inhibitors targeting the PI3K-PAK-Akt pathway in cancers.
Drug Developed by Target Clinical Trials Ref
GDC0941
Pictilisib
Genentech
/Roche
Pan class 1 PI3K
inhibitor
Completed Phase I/II trials for breast cancer, non-
small cell lung cancer, non-Hodgkin's lymphoma and 
advanced solid cancers. 
[138]
BX912 Berlex Bioscience PDK1 inhibitor N/A [148]
NVP-BEZ235 Novartis PI3K-mTOR inhibitor
Completed Phase I/II trials for breast cancer, 
leukemia,  castrate resistant prostate cancer , pancreatic 
neuroendocrine tumors and advanced solid tumors 
[149]
MK2206 Merck
Allosteric
Pan-AKT
inhibitor
Active Phase I/II trials for breast cancer, colon cancer, 
endometrial carcinoma, pancreatic adenocarcinoma, 
prostate cancer and renal cell carcinoma. Completed 
Phase I/II trials for breast cancer, acute and chronic 
myeloid leukemia, lung carcinoma, ovarian sarcoma, 
pancreatic acinar carcinoma, pancreatic neuroendocrine 
tumors and advanced solid tumors. 
[150]
AZD6244
Selumetinib
Array BioPharma
(Licensed by 
Astrazeneca) 
MEK1/2
inhibitor
Completed/Active Phase I/II trials for breast cancer, 
lung cancer, melanoma, pancreatic adenocarcinoma and 
solid tumors 
[151]
GSK-
1120212 GlaxoSmithKline
MEK1/2
Inhibitor
Completed/Active Phase I/II/III trials for lung cancer, 
melanoma, recurrent leukemia and solid tumors [152]
GSK
690693 GlaxoSmithKline
Akt 
inhibitor N/A [153]
FRAX597 Scripps ResearchInstitute
PAK1
inhibitor N/A [154]
PF-3758309 Pfizer PAK4 inhibitor N/A [144]
KPT-7189 Karyopharm PAK4inhibitor N/A [145]
LY294002 Eli Lilly ReversiblePI3K inhibitor Active Phase I for neuroblastoma [155]
NVP-
BKM120 Novartis
Pan class I PI3K 
inhibitor Active Phase III for metastatic breast cancer [156]
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catalytic domain in cells that are also overexpressing 
GEF-H1 allowing PAK4 phosphorylation of GEF-H1 to 
be readily detected; which was shown to be suppressed 
by PF-3758309 (IC50=1.3+/- 0.5nM). Subsequently, PF-
3758309 was found to inhibit cellular proliferation and 
anchorage independent growth across a panel of 92 cell 
lines including 28 PDAC lines. In the PDAC cell lines, the 
IC50 ranged from 12nM (Panc0813) to 2380 nM (HS700T) 
although it is not known whether this correlates with 
PAK4 expression. In tumor xenografts of colon, breast, 
lung, melanoma and stomach, PF-3758309 impaired 
tumor growth with a plasma EC50 of 0.4nM.
Pre-clinical results were encouraging and PF-
3758309 was subsequently tested in a phase 1 study of 33 
patients with advanced cancer, including two with PDAC 
[144]. This was the first and only clinical trial of a PAK4 
inhibitor thus far. Patients were treated with the drug 
orally in a standard 3+3 design and the median number of 
cycles was 3 (1-10). 9 patients had grade 3 or 4 adverse 
events and 2 had serious adverse events (abdominal pain 
and hemoptysis). 1 patient died from progressive disease 
whilst on treatment. The pharmacokinetic data revealed 
that after reaching Cmax within 5 hours of dosing, PF-
3758309 plasma concentration reduced in a multi-
exponential manner with an average terminal half-life of 
12.4 to 17.8 hours across doses. There was an absence 
of dose proportionality in the dose range of 10 to 60 
mg, which the investigators suggested was likely due to 
inter-patient variability. There were no tumor responses 
seen and the study was terminated due to unwarranted 
pharmacokinetic findings which were thought to be 
a result of excessive drug efflux, leading to off-target 
effects. Yet despite these disappointing preliminary results, 
the development of more specific PAK inhibitors are 
underway. It may be that improved specificity can reduce 
some the off target effects seen with the Pan-PAK inhibitor. 
In addition, understanding the link between PAK and the 
PI3K pathway may help identify predictive biomarkers 
which would help to better identify those patients who 
may benefit from targeted PAK therapy.
A small molecule PAK4 allosteric modulator KPT-
7189 has been shown to suppress PAK4 protein expression 
in PDAC cell lines, with associated significant reduction in 
cell proliferation [145]. Moreover, KPT-7189 inhibited the 
spheroid forming ability of PDAC cells with suppression 
of EMT and CSC markers. Pre-clinical efficacy studies 
using a similar anti-PAK4 therapeutic, KPT-7189 with 
KRAS mutated mice are on-going.
There is also evidence that PAK inhibitors may be 
used in combination with traditional chemotherapy or used 
in disease that is chemo-refractory. In 3 PDAC cell lines, 
Capan-2, PANC1 and SNU-410 that were found to be 
resistant to gemcitabine, the addition of the PAK4 siRNA 
appeared to have an effect on cell viability compared 
with SIRNA silencing of PAK4 or chemotherapy alone 
suggesting the combination of chemotherapy and PAK4 
inhibition warrants further investigation[146]
Ideally, any targeted anti-cancer treatment will 
be used alongside known predictive biomarkers to 
identify patients that will benefit from treatment. A 
disease as complex as PDAC, is likely to require tailored 
management rather than a ‘one hat fits all’ approach. 
The failure of several targeted agents in clinical trials 
is disappointing but perhaps not surprising given the 
heterogeneous nature of this disease. It is possible that 
drugs will only work in a sub-group of patients if their 
complementary pathway is aberrantly activated and pre-
determined biomarkers are needed to ensure that potential 
positive responses are not diluted in large clinical trials. 
Furthermore even when an effective target is identified, 
clinical responses are often followed by progression due 
to the development of resistance as seen in patients with 
BRAF mutated melanoma treated with BRAF mutant 
inhibitors [147]. Therefore, a greater understanding of 
pertinent pathways and novel targets are warranted.
PAK expression in the tumor tissue and genomic 
amplification may provide both a prognostic and 
predictive biomarker for novel therapies. For example, if 
PAK inhibition can modulate the PI3K pathway, activity 
of AKT may prove to be surrogate marker of efficacy. 
Conversely, elevated PAK expression may help identify 
patients that would benefit from inhibitors of the PI3K 
pathway.
FUTURE DIRECTIONS
PDAC is a devastating cancer with a lack of 
effective therapies for patients with advanced disease. 
Whilst KRAS mutations occur at a frequency of nearly 
100% in PDAC, the challenges of inhibiting RAS have 
meant efforts have been diverted to unraveling the 
interacting pathways both downstream from RAS, and 
those which are independent from RAS. The PAKs have 
been identified as a potential prognostic marker in several 
malignancies and their proposed links to the PI3K pathway 
warrant further attention. Despite the disappointment of 
several negative clinical trials, great strides have been 
made in improving our understanding of PDAC biology. 
This enhanced knowledge will hopefully translate into 
the development of effective targeted therapies, finally 
resulting in a much-needed improvement in the treatment 
of patients with PDAC.
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